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Abstract
Aims Urgent revascularization is the mainstay of treatment in acute coronary syndrome (ACS) related cardiogenic shock (CS).
The aim was to investigate the association of angiographic results with 90-day mortality. Procedural complications of percu-
taneous coronary intervention (PCI) were also examined.
Methods and results This CardShock (NCT01374867) substudy included 158 patients with ACS aetiology and data on coro-
nary angiography and complications during PCI procedure. Survival analysis was conducted with Kaplan–Meier curves and Cox
regression analysis. Median age was 67 ± 11 years, and 77% were men. During 90-day follow-up, 66 (42%) patients died. Pa-
tients with one-vessel disease (n = 49) had lower mortality than patients with two-vessel (n = 59) or three-vessel (n = 50) dis-
ease (25% vs. 48% vs. 52%, P = 0.011). Successful revascularization [Thrombolysis in Myocardial Infarction (TIMI) Flow 3 post-
PCI) was achieved more often in survivors than non-survivors (81% vs. 60%, P = 0.019). The median symptom-to-balloon time
was 340 (196–660) minutes, with no difference between survivors and non-survivors. In multivariable mortality analysis,
multivessel disease (HR 2.59, CI95% 1.29–5.18) and TIMI flow <3 post-PCI (HR 2.41, CI95% 1.4–4.15) were associated with
90-day mortality. Procedural PCI complications were recorded in 51 (35%) patients, arrhythmic complications being the most
common (n = 32, 63%). The incidence of complications was similar between survivors and non-survivors (31% vs. 42%, P =
0.21).
Conclusions Multivessel disease is associated with worse survival in ACS-related CS. In patients undergoing PCI, arrhythmic
complications were common, but not associated with excess mortality. Successful revascularization of the IRA had positive ef-
fect on outcome despite delay from symptom onset.
Keywords Cardiogenic shock; Acute coronary syndrome; Percutaneous coronary intervention
Received: 10 October 2019; Revised: 15 January 2020; Accepted: 21 January 2020
*Correspondence to: Tuija Sabell, MD, Heart and Lung Center, Helsinki University Hospital, PO Box 340, 00029 HUS, Helsinki, Finland.
Email: tuija.sabell@outlook.com
†This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
Background
Urgent coronary angiography and revascularization are the
mainstay of treatment in acute coronary syndrome (ACS) re-
lated cardiogenic shock (CS).1 In previous studies,
multivessel2–4 and three-vessel coronary artery disease
(CAD),5–8 unsuccessful revascularization,3–5,7–11 and left main
(LM) CAD3,5,7 have been associated with poor outcomes in
ACS-related CS. However, many of these studies
predate the primary percutaneous coronary intervention
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(PCI) era,5–7 were of retrospective nature10,12 or examined
registry data.3,8,11 Furthermore, data on procedural PCI com-
plications in ACS-related CS are scarce.
Aims
The aim of this study was to explore coronary angiographic
findings in a prospective multicentre cohort of ACS-related
CS. The primary objective was to investigate the association
of angiographic results and 90-day mortality. In addition, pro-
cedural PCI complications were examined.
Methods
The CardShock study (NCT01374867) is a prospective multi-
national study on CS conducted in nine centres in eight Euro-
pean countries between October 2010 and December 2012.
The description of the study cohort has been reported previ-
ously.13 Briefly, consecutive patients aged over 18 years were
enrolled within 6 h from detection of CS. The criteria for
shock were systolic blood pressure <90mmHg for 30min de-
spite adequate fluid therapy or need for vasoactive therapy,
and ≥1 signs of inadequate organ perfusion: confusion or al-
tered mental status, cool extremities, oliguria <0.5 mL/kg/h
for the previous 6 h, or blood lactate >2 mmol/L.
Patients’ characteristics, medical history, clinical signs, and
laboratory measurements were registered. Echocardiogram
was performed at study baseline. Patients were treated ac-
cording to local practise. Information on angiographic find-
ings and revascularisation procedures were collected.
This sub-study included patients with ACS aetiology and
data on coronary angiography. The primary endpoint was
all-cause mortality at 90 days. The vital status was confirmed
by the patient or next of kin, or through hospital or popula-
tion registers. The study was approved by local ethics com-
mittees and conducted in accordance with the Declaration
of Helsinki.
Data are presented as means and standard deviations
(SDs), medians and interquartile ranges (IQRs), or as counts
and percentages. Comparisons between groups were
analysed by Student’s t-test or Mann–Whitney U-test for con-
tinuous variables and χ2 test or Fisher’s exact test for categor-
ical variables, as appropriate.
Survival was analysed using Kaplan–Meier curves and log-
rank tests. The association with 90-day mortality was
assessed by univariate Cox regression for the following vari-
ables selected a priori: age, gender, comorbidities [prior myo-
cardial infarction or coronary artery bypass grafting (CABG),
diabetes, hypertension, and smoking], estimated glomerular
filtration rate (eGFR), levels of lactate, high sensitivity tropo-
nin T (hs-TnT) and N-terminal pro brain natriuretic peptide
(NT-proBNP) at baseline, left ventricular ejection fraction
(LVEF), multivessel CAD (significant stenosis in more than
one main coronary vessel or major side branch), stenosis of
LM, infarct related artery (IRA), thrombolysis prior to angiog-
raphy, intra-aortic balloon pump (IABP), CABG during hospital
stay, PCI, symptom-to-balloon time, number of stents, drug-
eluting stent, metal stent, amount of contrast agent, pre-
procedural Thrombolysis in Myocardial Infarction (TIMI)
grade 0/1 flow, TIMI flow<3 post-PCI, and PCI complications.
The variables with P value <0.10 in univariate analysis were
included in the multivariable analysis. The final model was
built with backward stepwise method with Cox regression
analysis. A two-tailed P value of <0.05 was considered statis-
tically significant. The statistical analyses were performed
using R statistical software version 3.4.3 (The “R” Foundation
for Statistical Computing, Vienna, Austria).
Results
In total, 177 CardShock patients had ACS aetiology. Of these
patients, 10 did not undergo angiographic evaluation, six pa-
tients did not have data on angiographic findings, and three
were lost to follow-up. Finally, 158 patients were included in
this study. Median age was 67 ± 11 years, and 121 (77%)
were male. During the 90-day follow-up, 66 (42%) patients
died. Baseline characteristics are described in Table 1. Survi-
vors were younger (66 ± 12 vs. 70 ± 9 years, P = 0.029), had
fewer comorbidities, and had higher LVEF (38% ± 14 vs. 29%
± 12, P < 0.001) than non-survivors (Table 1).
Patients with one-vessel CAD (n = 49, 31%) had lower 90-
day mortality than patients with two- (n = 59, 37%) or three-
(n = 50, 32%) vessel CAD (25% vs. 48% vs. 52%, respectively;
P = 0.011, Figure 1A). Mortality was numerically higher in
patients with LM or left anterior descending (LAD) as the
culprit artery when compared to right coronary artery
(RCA) or LCX, but the difference was not statistically signifi-
cant. Successful revascularization (TIMI Flow 3 post-PCI)
was achieved more often in survivors than in non-survivors
(81% vs. 60%, P = 0.019, Table 1, Figure 1C), whereas there
were no differences in the rate of successful revasculariza-
tion between different IRAs: 72% in LM, 70% in LAD, 59%
in LCX, 77% in RCA, and 80% in saphenous vein graft (SVG)
(P = 0.67). The median symptom-to-balloon time was 340
(196-660) minutes, with no difference between groups
(Table 1). One-third of the patients (n = 49, 36%) developed
shock only after the PCI procedure, but there was no differ-
ence in the rate of successful revascularization, if shock de-
veloped before or after the procedure (32% vs. 24%, P =
0.41).
In multivariable analysis, multivessel CAD (HR 2.59, CI95%
1.29–5.18, P = 0.007), TIMI flow <3 post-PCI (HR 2.41, CI95%
1.4–4.15, P = 0.001), increasing lactate (HR 1.17, CI95% 1.11–
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1.23, P < 0.001), and decreasing LVEF (HR 1.03, CI95% 1.01–
1.06, P = 0.002) were independently associated with 90-day
mortality.
Any procedural complication was recorded in 35% of the
patients who underwent PCI with no difference between sur-
vivors and non-survivors (31% vs. 42%, P = 0.21, Table 1).
Table 1 Baseline and angiographic characteristics
All patients (n = 158) Survivors (n = 92) Non-survivors (n = 66) P
Age 67 ± 11 66 ± 12 70 ± 9 0.029
Male gender 121 (77) 75 (82) 46 (70) 0.12
ACS type: STEMI 139 (88) 80 (87) 59 (89) 0.83
Medical history
Known coronary artery disease 49 (31) 21 (23) 28 (42) 0.014
Prior myocardial infarction 36 (23) 14 (15) 22 (33) 0.013
Prior PCI 22 (14) 10 (11) 12 (18) 0.28
CABG 9 (6) 1 (1) 8 (12) 0.009
Chronic heart failure 10 (6) 2 (2) 8 (12) 0.03
Clinical characteristics
CardShock risk score 4 ± 2 4 ± 2 5 ± 1 <0.001
Systolic blood pressure 78 ± 14 80 ± 15 75 ± 12 0.025
LVEF 34 ± 14 38 ± 14 29 ± 12 <0.001
Laboratory tests
Lactate (mmol/L) 3 [2-5] 2 [1-4] 4 [3-8] <0.001
eGFR (mL/min/1.73 m2) 63 [44-87] 71 [51-96] 49 [33-70] <0.001
hs-TnT (ng/L) 3205 [1167-8907] 2614 909-6940] 4010 [1628-10993] 0.08
NT-proBNP (ng/L) 1751 [374-8602] 1077 [252-5029] 3769 [648-12249] 0.01
Characteristics of CAD
Number of diseased vessels 0.011
One-vessel disease 49 (31) 37 (40) 12 (18)
Two-vessel disease 59 (37) 31 (34) 28 (42)
Three-vessel disease 50 (32) 24 (26) 26 (39)
IRA 0.005
LAD 63 (40) 33 (36) 30 (47)
LCX 21 (14) 16 (17) 5 (8)
LM 19 (12) 9 (10) 10 (16)
RCA 48 (31) 34 (37) 14 (22)
SVG 5 (3) 0 (0) 5 (8)
Treatment
PCI 144 (91) 82 (89) 62 (94) 0.44
Thrombolysis 17 (11) 13 (14) 4 (6) 0.18
IABP 103 (65) 55 (60) 48 (73) 0.13
CABG 8 (5) 7 (8) 1 (2) 0.18
Procedural characteristics n = 144 n = 82 n = 62
Symptom-to-balloon time (min) 340 [196–660] 335 [210–641] 340 [190–660] 0.70
Bare metal stent 66 (46) 39 (48) 27 (44) 0.76
Multivessel PCI 38 (26) 21 (26) 17 (27) 0.96
PCI of LM 21 (15) 8 (10) 13 (21) 0.11
Total occlusion (pre-procedural TIMI 0/1) 119 (84) 65 (80) 54 (89) 0.27
Post-procedural TIMI 0.027
0/1 15 (11) 6 (7) 9 (15)
2 25 (18) 10 (12) 15 (25)
3 102 (72) 66 (81) 36 (60)
Amount of contrast agent (mL) 160 [120-220] 170 [120-210] 160 [124-250] 0.66
Shock after PCI 49 (36) 33 (41) 16 (28) 0.16
Complications
Any PCI complication 51 (35) 25 (31) 26 (42) 0.21
Ventricular tachycardia or fibrillation 27 (19) 11 (13) 16 (26) 0.10
Bradycardia 21 (15) 7 (9) 14 (23) 0.034
Dissection 8 (6) 5 (6) 3 (5) 1.00
Tamponade 1 (1) 1 (1) 0 (0) 1.00
Re-occlusion 4 (3) 1 (1) 3 (5) 0.43
Re-coronary angiography 12 (9) 10 (13) 2 (3) 0.10
Re-PCI 10 (7) 8 (10) 2 (3) 0.22
ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; CAD, coronary artery disease, CRP, C reactive protein; eGFR, esti-
mated glomerular filtration rate; hs-TnT, high-sensitive troponin T; IABP, intra-aortic balloon pump; IRA, infarct related artery; LAD, left
anterior descending coronary artery; LCX, left circumflex coronary artery; LM, left main coronary artery; LVEF, left ventricular ejection frac-
tion; MAP, mean arterial pressure; NT-proBNP, N-terminal pro brain natriuretic peptide; PCI, percutaneous coronary intervention; RCA,
right coronary artery; STEMI, ST-segment elevation myocardial infarction; SVG, saphenous vein graft; TIMI, Thrombolysis in Myocardial
Infarction.
Data are presented as means ± standard deviation, medians (interquartile range) or counts (%).
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Arrhythmia was the most common complication: 19% had
ventricular tachycardia or fibrillation, and bradycardia was re-
corded in 15% of patients. Bradycardia was more frequent in
non-survivors than survivors (23% vs. 9%, P = 0.034), but in
adjusted mortality analysis, bradycardia was not associated
with the risk of 90-day death (HR 1.09, CI95% 0.51–2.35, P =
0.82).
Conclusion
In this study, multivessel CAD and TIMI flow <3 post-PCI
were associated with poor prognosis in ACS-related
CS. Among patients undergoing PCI, arrhythmic
complications were common but not associated with excess
mortality.
Multivessel CAD was associated with worse survival in ACS-
related CS, as previously shown.2,3,5–8 No difference in mor-
tality between different IRAs was discovered, similar to one
previous study,4 even though mortality rates were
numerically higher in LM and LAD in comparison to RCA and
LCX. In other studies, LM as the culprit artery has been asso-
ciated with worse survival,3,5,7,11 whereas RCA as the culprit
artery has been associated with better prognosis.6,12 The pro-
portion of patients with successful revascularization was sim-
ilar irrespective of the culprit artery, which suggests that high
mortality rates of LM and LAD were not related to procedural
failure. Indeed, the culprit vessel may only play minor role in
survival in CS, especially when revascularization is successful,
as mortality may be more strongly associated with haemody-
namic instability and multi-organ damage.
Our study confirms that successful revascularization of the
IRA is associated with good prognosis.3,5,7–11 In our study, the
median symptom-to-balloon time was suboptimal with a me-
dian delay of 6 h. Nevertheless, there was no difference in PCI
timing between survivors and non-survivors. As we examined
symptom-to-balloon time and not contact-to-balloon time,
our results are not directly comparable to the FITT-ST-
segment elevation myocardial infarction (STEMI) trial,14 yet
our results show that in CS, even delayed successful
Figure 1 Kaplan–Meier 90-day survival curves in different patient groups divided by (A) severity of coronary artery disease, (B) the infarct related ar-
tery, and (C) the Thrombolysis in Myocardial Infarction flow post-percutaneous coronary intervention. (A) Patients with one-vessel disease had lower
90-day mortality rates than patients with two-vessel or three-vessel disease. (B) Patients with left anterior descending coronary artery or left main
coronary artery as the infarct related artery had high mortality rates. (C) Patients with successful revascularization, i.e. TIMI Flow 3, had lower mortality
rates than patients with TIMI Flows 0–2.
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revascularization is associated with improved prognosis.
However, some factors should be taken in consideration.
We did not record specific reasons for the delay in
symptom-to-balloon time, such as patient-related delays to
first medical contact, or transfer times. In addition, not all pa-
tients were in shock on arrival to the hospital but developed
shock only after the revascularisation procedure. In patients
with ACS, delayed revascularisation may predispose to later
development of shock,15 but the timing of PCI was similar be-
tween survivors and non-survivors, and there was no differ-
ence in the rate of successful revascularisation if shock
developed before or after PCI. Despite prolonged symptom-
to-balloon time, TIMI Flow 3 post-PCI was still associated with
better outcome, indicating that successful revascularization
may be a more important driver for improved prognosis than
timing of the procedure.
We found no difference in survival with culprit-vessel only
or multivessel PCI, in contrary to the CULPRIT-SHOCK trial.16
The evident difference between our study and the CULPRIT-
SHOCK trial is that our study was of prospective nature, which
enabled the treating physician to select the most suitable pa-
tients to the multivessel PCI. In addition, some of the patients
included in this study did not have CS during the PCI
procedure.
The rate of procedural PCI complications was higher than
reported in STEMI,17 and slightly higher than in a registry
study of ACS-related CS11. However, the rate of ventricular
arrhythmias was similar to previously reported STEMI-related
CS10. In this critically ill population, arrhythmic events were
most likely related to the severity of the disease and not to
the revascularisation procedure itself. Indeed, procedural
complications did not associate with mortality, suggesting
that they are transient and treatable. During PCI in CS, imme-
diate actions, such as defibrillation and cardiac pacing, should
be readily available for management of arrhythmic
complications.
There are limitations to be acknowledged. Though this
study is considerable for a prospective study of CS, the num-
ber of patients in some groups was low. In addition, the
examination of angiograms was not centralized, but the pa-
tients were treated, and the results were reported, by expe-
rienced interventional cardiologists.
In conclusion, multivessel disease is associated with worse
survival in ACS-related CS. In patients undergoing PCI, ar-
rhythmic complications were common, but not associated
with excess mortality. Successful revascularization of the
IRA had a positive effect on outcome despite delay from
symptom onset. Thus, in CS, even late PCI seems to be
feasible.
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